On May 3, 2022 Agendia, Inc. , a commercial-stage company focused on facilitating optimized decision-making by providing clinicians with next-generation information and diagnostic solutions that can be used to help improve outcomes of breast cancer patients worldwide, reported that it will present new data at the European Society for Medical Oncology Breast Cancer Conference 2022 (ESMO Breast 2022) in Berlin, Germany, from 3 to May 5, 2022 (Press release, Agendia, MAY 3, 2022, View Source [SID1234613434]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first of two poster presentations, titled Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests [234P], concludes that the sequencing version MammaPrint and BluePrint [1] Next-Generation Microarray Testing (NGS) is equivalent to centralized microarray testing, as evidenced by results from several laboratories worldwide. This enables a more accurate decentralized solution for breast cancer care, promoting global accessibility to more reliable genomic tests.
"Accessibility to breast cancer care is crucial and by validating the interchangeability of the NGS version of MammaPrint and BluePrint compared to standardized microarray tests, it opens new doors for clinicians around the world who may need to rely on platforms in the country to secure the MammaPrint and BluePrint results that their patients may need," says Annuska Glas, Senior Vice President of Research and Development and Innovation at Agendia. "MammaPrint is a valuable tool to aid treatment planning for breast cancer patients and with the decentralized NGS platform, it can be offered in even more countries. These results confirm that MammaPrint and BluePrint can provide the same accurate results through of NGS," he adds.
Agendia is creating new ways to ensure accessibility of care around the world, advancing solutions with a decentralized option for test kits to run on an NGS platform, and innovative modalities such as AI digital pathology. This data presented at the ESMO (Free ESMO Whitepaper) Breast 2022 conference follows Agendia’s announcement earlier this year that it was advancing its Digital MammaPrint artificial intelligence (AI) platform in Brazil to potentially radically change the way breast cancer is treated, providing essential information faster and elevating the capabilities of global clinicians treating women with breast cancer in their local communities.
A second poster presentation, entitled Budget impact analysis for the Health Care Package by using MammaPrint in Belgium [238P],builds on earlier research from the landmark MINDACT trial and combines it with interim analysis results from the pilot study conducted in Belgium (unpublished data). The budget impact model shows that the use of MammaPrint results in savings in breast cancer care in Belgium for the Belgian health package compared to no gene expression profiling testing. According to the budget impact model, the use of MammaPrint in patients selected according to the criteria of the pilot study represents a great saving. If gene expression profiling were performed on all clinically high-risk patients, the savings would be even greater.
Combining the cost of genomic testing with the savings from the net reduction in chemotherapy use, the annual savings amount to more than €5.8 million, which is an average saving of €3,900 per patient, compared to standard clinical care of a patient with breast cancer in Belgium. MINDACT has carried out previous analyzes of health savings in several countries, published in the European Journal of Cancer ,showing that genomic testing is beneficial as it provides valuable information that potentially allows patients to avoid the complexity of chemotherapy, resulting in significant financial savings for them, while generating significant cost savings for large healthcare systems around the world.
"A partir de los datos de impacto utilizados en el estudio piloto realizado en Bélgica, podemos determinar nuevas ideas de que el uso de MammaPrint podría conceder un ahorro sustancial de costes a las mujeres que no requieran quimioterapia y, en última instancia, podría aliviar parte de la carga del sistema sanitario belga en su conjunto", señala Pino Cusumano, MD, cirujano de mama del Centre Hospitalier Chrétien de Lieja en Bélgica. "Los datos han demostrado previamente que al desescalar a las mujeres con casos de bajo riesgo del tratamiento de quimioterapia, los resultados siguen siendo igual de buenos y las mujeres pueden seguir un plan de tratamiento más personalizado. Creemos que estos datos demuestran que el análisis anterior es válido para el estado de la atención del cáncer de mama en Bélgica en 2022,and that the overall benefit to the patient extends beyond physical care, to financial well-being as well," he continues.
Taken together, the two posters presented at ESMO (Free ESMO Whitepaper) Breast 2022 suggest that no matter where a patient is located, she can receive the same high-quality results with the added benefit of cost-effective treatment planning.
"The studies presented at EMSO 2022 support Agendia’s key initiatives to ensure that our genomic tests are widely accessible and affordable, without compromising scientific integrity or decision-making, to provide the clarity that women with breast cancer seek to guide treatment planning," says Bastiaan van der Baan, Director of Clinical and Commercial Development at Agendia. "With our strong commitment to facilitating the global adoption of MammaPrint and BluePrint, we look forward to continuing studies like these to increase the evidence supporting our goal of caring for women with breast cancer throughout their treatment," he concludes.
1 The MammaPrint and BluePrint next-generation sequencing kits have not yet been cleared by the Food and Drug Administration for sale in the United States; BluePrint has received CE marking for use in Europe. BluePrint is also marketed as a Laboratory Developed Test (LDT) and is CAP/CLIA audited in the United States.